COMPARATIVE UPTAKE, RETENTION AND CYTOTOXICITY OF DAUNORUBICIN BY HUMAN MYELOID CELLS

被引：8

作者：

VASANTHAKUMAR, G ^{[1
]}

AHMED, NK ^{[1
]}

机构：

[1] ST JUDE CHILDRENS RES HOSP,DIV BIOCHEM & CLIN PHARMACOL,MEMPHIS,TN 38101

来源：

BIOCHEMICAL PHARMACOLOGY | 1986年 / 35卷 / 07期

关键词：

D O I：

10.1016/0006-2952(86)90158-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

引用

页码：1185 / 1190

页数：6

共 32 条

[1] DAUNORUBICIN REDUCTASE-ACTIVITY IN HUMAN NORMAL LYMPHOCYTES, MYELOBLASTS AND LEUKEMIC-CELL LINES [J].

AHMED, NK .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (10) :1209-1213

[2] DAUNORUBICIN REDUCTION MEDIATED BY ALDEHYDE AND KETONE REDUCTASES [J].

AHMED, NK ;

FELSTED, RL ;

BACHUR, NR .

XENOBIOTICA, 1981, 11 (02) :131-136

[3] HETEROGENEITY OF ANTHRACYCLINE ANTIBIOTIC CARBONYL REDUCTASES IN MAMMALIAN LIVERS [J].

AHMED, NK ;

FELSTED, RL ;

BACHUR, NR .

BIOCHEMICAL PHARMACOLOGY, 1978, 27 (23) :2713-2719

[4]

AHMED NK, 1979, J PHARMACOL EXP THER, V209, P12

[5] QUANTITATION OF DAUNORUBICIN AND ITS METABOLITES BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].

AKPOFURE, C ;

RILEY, CA ;

SINKULE, JA ;

EVANS, WE .

JOURNAL OF CHROMATOGRAPHY, 1982, 232 (02) :377-383

[6]

ANDERSSON B, 1982, CANCER RES, V42, P178

[7] ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY [J].

BLUM, RH ;

CARTER, SK .

ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) :249-259

[8]

BOSSMANN HB, 1971, FEDN EUR BIOCH SOC L, V15, P273

[9]

DANO K, 1972, CANCER RES, V32, P1307

[10]

DANO K, 1972, CANCER CHEMOTH REP 1, V56, P321

← 1 2 3 4 →